TMFFishBiz’s Activity

Thu Nov 17

NL

Article

TMFFishBiz published an article 9:21 AM

3 Things Exelixis Must Do to Survive and Thrive in 2017

Exelixis CEO Mike Morrissey explains what his company needs to do to succeed in the days ahead at the Stifel Healthcare Conference in New York.

NL

Article

TMFFishBiz published an article 9:03 AM

3 Compelling Reasons to Buy Celgene Corporation Stock Right Now

Celgene's inflammation and immunology pipeline provides plenty of reasons to buy this biotech stock.

Wed Nov 16

NL

Article

TMFFishBiz published an article 4:41 PM

3 Potential Acquisition Targets for Gilead Sciences, Inc.

Gilead Sciences is ready to shop. Here's why Kite, Tesaro, and Intercept might be good selections to add to the biotech's cart.

NL

Article

TMFFishBiz published an article 4:27 PM

The Scariest Thing About Pfizer's Dividend

Should investors be spooked by the drugmaker's sky-high dividend payout ratio?

Tue Nov 15

NL

Article

TMFFishBiz published an article 5:41 PM

Better Buy: Johnson & Johnson vs. Merck

Johnson & Johnson has Imbruvica. Merck has Keytruda. Which of these 2 giant drugmakers with superstar cancer drugs is the better pick for long-term investors?

NL

Article

TMFFishBiz published an article 11:04 AM

Teva Pharmaceutical Industries Ltd.'s Q3 Helped by Actavis Generics Deal -- but Not Quite Enough

The generic and specialty drugmaker posts big jumps in revenue and earnings thanks to its acquisition earlier this year of Actavis' generics business.

Income Investor article.

TMFFishBiz published an update. 9:27 AM

NL

Article

TMFFishBiz published an article 8:03 AM

Dynavax Technologies Shares Decimated -- Is There Any Hope for Heplisav?

The FDA rejects Dynavax's hepatitis B vaccine for the second time. What's next for the jinxed biotech?

NL

Article

TMFFishBiz published an article 7:03 AM

Better Buy: Biogen Inc. vs. Celgene Corporation

Which stock wins in this battle of big biotechs: Biogen or Celgene?

Mon Nov 14

NL

Article

TMFFishBiz published an article 4:28 PM

Go for It, Pfizer -- Sell Your Consumer Healthcare Business

The drugmaker is reportedly looking at selling or spinning off its consumer healthcare business. Here's why the company should take the plunge.

Rule Breakers article.

TMFFishBiz published an update. 12:19 AM

Sun Nov 13

NL

Article

TMFFishBiz published an article 9:07 AM

7 Steps to Picking the Right Medicare Part D Plan for You

Looking for the right Medicare Part D plan that best meets your needs? Here's how to do it in seven simple steps.

NL

Article

TMFFishBiz published an article 7:43 AM

3 Drugmakers That Probably Have Lower Tax Rates Than You Do

Here's why Amgen, Gilead Sciences, and Lilly just might have paid a lower effective tax rate than you did in 2015.

Sat Nov 12

NL

Article

TMFFishBiz published an article 8:09 AM

The Potential and Peril with Inovio Pharmaceuticals, Inc.

Buying Inovio comes with huge risks. But the biotech also could give investors huge rewards.

Fri Nov 11

NL

Article

TMFFishBiz published an article 1:23 PM

Juno Therapeutics On a Roll in Q3 with Celgene's Cash and Lift of Clinical Hold

The clinical-stage biotech's revenue soars in Q3 thanks to Celgene exercising licensing rights on the CD19 program.

Thu Nov 10

NL

Article

TMFFishBiz published an article 4:42 PM

5 Things Mylan's Management Wants You to Know

Mylan reported its Q3 results on Wednesday. Here's what you need to know about what the drugmaker's executives had to say.

NL

Article

TMFFishBiz published an article 3:41 PM

What's Next for Arrowhead Pharmaceuticals, Inc. After the Stock Meltdown?

Arrowhead's stock cratered after the announcement of an FDA clinical hold. Can the biotech make a comeback?

NL

Article

TMFFishBiz published an article 8:02 AM

How Much Is Organovo Holdings, Inc. Really Worth?

Organovo is bouncing back. How high can it go?

Stock Advisor article.

TMFFishBiz published an update. 1:00 AM

Wed Nov 9

NL

Article

TMFFishBiz published an article 6:23 PM

Acquisitions and International Sales Growth Help Mylan N.V. in Q3

The generic and specialty drugmakers continues to face political pressure but posted solid revenue growth in Q3.

Show More Activity ...

CAPS Stats & Trivia

CAPS Player Rating < 20
Player Rank 0 out of 74749
Score 0.00
Score Change Today +9.87
Accuracy 0.00%
Active Picks 6
Total Picks 19
Best Pick QCOR.DL (+221.68)
Worst Pick AMRN (-107.70)
Average Score per Pick -6.83
Charms Earned 2
Highest Rated Favorite No Favorites Selected
Go to TMFFishBiz’s CAPS page

Boards Stats & Trivia

Board Posts 0
Recs Received 0
People who have rec'd these posts 0
Recs to Posts Ratio (last 30 days) N/A
Threads Started 0
Threads Started Percentage 0.00 %
Most Frequent Board N/A
Very First Post N/A
Percentage of Posts Rec'd 100.00 %
Show TMFFishBiz’s 10 Latest Posts